Humanigen Inc (HGENQ)

[Fezziwig2008]

HGEN - Univ of New Mexico Global Health COVID19 Briefing ” Small study shows benefit of lenzilumab in high risk patients with severe pneumonia
MedRxiv preprint: Hospitalized patients with COVID-19 pneumonia and risk factors for poor outcomes were treated with lenzilumab 600 mg intravenously for three doses through an emergency single-use IND - Clinical improvement was seen in 11/12 (92%) with significant improvement in oxygenation and a median 5 day discharge” https://digitalrepository.unm.edu/cgi/viewcontent.cgi?article=1050&=&context=hsc_covid19_briefings&=&sei-redir=1&referer=https%253A%252F%252Fscholar.google.com%252Fscholar%253Fas_ylo%253D2020%2526q%253DLenzilumab%2526hl%253Den%2526as_sdt%253D0%252C33%2523d%253Dgs_qabs%2526u%253D%252523p%25253D1F5RMpvTnwoJ#search=%22Lenzilumab%22